UY38906A - Compuestos 2- derivados de azaspiro[3,4]octano como agonistas de m4 y composiciones de los mismos - Google Patents
Compuestos 2- derivados de azaspiro[3,4]octano como agonistas de m4 y composiciones de los mismosInfo
- Publication number
- UY38906A UY38906A UY0001038906A UY38906A UY38906A UY 38906 A UY38906 A UY 38906A UY 0001038906 A UY0001038906 A UY 0001038906A UY 38906 A UY38906 A UY 38906A UY 38906 A UY38906 A UY 38906A
- Authority
- UY
- Uruguay
- Prior art keywords
- compounds
- agonists
- compositions
- azaspiro
- octane
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
En la presente se proporcionan compuestos de acuerdo con la Fórmula (I) o una sal farmacéuticamente aceptable de los mismos, en donde R1, R2, R3, R5, y R7 se definen en la presente. También se proporcionan en la presente composiciones farmacéuticas que comprenden un compuesto de Fórmula (I) así como también el uso de dichos compuestos como agonistas del receptor M4.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962912980P | 2019-10-09 | 2019-10-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY38906A true UY38906A (es) | 2021-05-31 |
Family
ID=72944205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001038906A UY38906A (es) | 2019-10-09 | 2020-10-07 | Compuestos 2- derivados de azaspiro[3,4]octano como agonistas de m4 y composiciones de los mismos |
Country Status (21)
Country | Link |
---|---|
US (2) | US11548865B2 (es) |
EP (1) | EP4041389A1 (es) |
JP (1) | JP7349570B2 (es) |
KR (1) | KR20220079921A (es) |
CN (1) | CN114555592A (es) |
AR (1) | AR120170A1 (es) |
AU (1) | AU2020361735B2 (es) |
CA (1) | CA3156320A1 (es) |
CL (1) | CL2022000893A1 (es) |
CO (1) | CO2022004341A2 (es) |
CR (1) | CR20220141A (es) |
CU (1) | CU20220023A7 (es) |
EC (1) | ECSP22027287A (es) |
IL (1) | IL291316A (es) |
JO (1) | JOP20220082A1 (es) |
MX (1) | MX2022004213A (es) |
PE (1) | PE20221453A1 (es) |
TW (1) | TW202128649A (es) |
UY (1) | UY38906A (es) |
WO (1) | WO2021070090A1 (es) |
ZA (1) | ZA202202912B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020361735B2 (en) * | 2019-10-09 | 2024-04-18 | Novartis Ag | 2-azaspiro(3.4)octane derivatives as M4 agonists |
WO2024059249A1 (en) * | 2022-09-16 | 2024-03-21 | Cerevel Therapeutics, Llc | M4 activators/modulators and uses thereof |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060276520A1 (en) | 2002-11-13 | 2006-12-07 | Rigel Pharmaceuticals, Inc. | Rhodanine derivatives and pharmaceutical compositions containing them |
US7479496B2 (en) | 2004-02-19 | 2009-01-20 | Bristol-Myers Squibb Company | Substituted spiro azabicyclics as modulators of chemokine receptor activity |
WO2006006490A1 (ja) | 2004-07-08 | 2006-01-19 | Ono Pharmaceutical Co., Ltd. | スピロ化合物 |
US7880007B2 (en) * | 2004-11-29 | 2011-02-01 | Vertex Pharmaceuticals Incorporated | Bicyclic substituted phenyl piperidine modulators of muscarinic receptors |
EP2064187A2 (en) | 2006-08-25 | 2009-06-03 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
WO2010049146A1 (en) | 2008-10-29 | 2010-05-06 | Grünenthal GmbH | Substituted spiroamines |
BRPI1007350B8 (pt) | 2009-01-26 | 2021-05-25 | Israel Institute For Biological Res | compostos espiro heterocíclicos bicíclicos |
CA2827311A1 (en) | 2011-02-18 | 2012-08-23 | Vertex Pharmaceuticals Incorporated | Chroman-spirocyclic piperidine amides as modulators of ion channels |
EP2739617A4 (en) | 2011-07-27 | 2015-01-28 | Nanjing Allgen Pharma Co Ltd | SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS |
EP2892902A1 (en) | 2012-09-07 | 2015-07-15 | Zoetis LLC | Spirocyclic derivatives as antiparasitic agents |
AU2013319989C1 (en) | 2012-09-18 | 2017-08-17 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic M1 receptor agonists |
US9670183B2 (en) * | 2014-02-06 | 2017-06-06 | Heptares Therapeutics Limited | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor agonists |
WO2016067043A1 (en) | 2014-10-31 | 2016-05-06 | Indivior Uk Limited | Dopamine d3 receptor antagonists compounds |
GB201504675D0 (en) * | 2015-03-19 | 2015-05-06 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201513742D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
GB201513743D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
GB201513740D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
BR122024002146A2 (pt) | 2016-06-10 | 2024-03-05 | Vitae Pharmaceuticals, Inc. | Compostos inibidores da interação de menina-llm e forma cristalina destes |
GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
CN108456208B (zh) | 2017-02-22 | 2021-04-16 | 广州市恒诺康医药科技有限公司 | 氮杂螺环类化合物及其制备方法和应用 |
WO2018175746A1 (en) | 2017-03-24 | 2018-09-27 | Kura Oncology, Inc. | Methods for treating hematological malignancies and ewing's sarcoma |
GB201709652D0 (en) * | 2017-06-16 | 2017-08-02 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
CN112154145B (zh) | 2018-03-23 | 2023-10-17 | 辉瑞大药厂 | 哌嗪氮杂螺衍生物 |
GB201810245D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
AU2020361735B2 (en) * | 2019-10-09 | 2024-04-18 | Novartis Ag | 2-azaspiro(3.4)octane derivatives as M4 agonists |
JOP20220084A1 (ar) * | 2019-10-09 | 2023-01-30 | Novartis Ag | مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 |
-
2020
- 2020-10-07 AU AU2020361735A patent/AU2020361735B2/en active Active
- 2020-10-07 US US17/065,360 patent/US11548865B2/en active Active
- 2020-10-07 JP JP2022521118A patent/JP7349570B2/ja active Active
- 2020-10-07 EP EP20793460.5A patent/EP4041389A1/en active Pending
- 2020-10-07 JO JOP/2022/0082A patent/JOP20220082A1/ar unknown
- 2020-10-07 CA CA3156320A patent/CA3156320A1/en active Pending
- 2020-10-07 CR CR20220141A patent/CR20220141A/es unknown
- 2020-10-07 TW TW109134714A patent/TW202128649A/zh unknown
- 2020-10-07 WO PCT/IB2020/059430 patent/WO2021070090A1/en active Application Filing
- 2020-10-07 CU CU2022000023A patent/CU20220023A7/es unknown
- 2020-10-07 UY UY0001038906A patent/UY38906A/es unknown
- 2020-10-07 AR ARP200102775A patent/AR120170A1/es unknown
- 2020-10-07 MX MX2022004213A patent/MX2022004213A/es unknown
- 2020-10-07 CN CN202080071012.7A patent/CN114555592A/zh active Pending
- 2020-10-07 PE PE2022000553A patent/PE20221453A1/es unknown
- 2020-10-07 KR KR1020227015315A patent/KR20220079921A/ko unknown
-
2022
- 2022-03-10 ZA ZA2022/02912A patent/ZA202202912B/en unknown
- 2022-03-13 IL IL291316A patent/IL291316A/en unknown
- 2022-04-05 CO CONC2022/0004341A patent/CO2022004341A2/es unknown
- 2022-04-06 EC ECSENADI202227287A patent/ECSP22027287A/es unknown
- 2022-04-07 CL CL2022000893A patent/CL2022000893A1/es unknown
- 2022-12-06 US US18/062,356 patent/US20230212139A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CR20220141A (es) | 2022-05-03 |
ECSP22027287A (es) | 2022-12-30 |
JP2022552244A (ja) | 2022-12-15 |
JP7349570B2 (ja) | 2023-09-22 |
CA3156320A1 (en) | 2021-04-15 |
MX2022004213A (es) | 2022-05-03 |
AU2020361735A1 (en) | 2022-04-21 |
JOP20220082A1 (ar) | 2023-01-30 |
IL291316A (en) | 2022-05-01 |
US20230212139A1 (en) | 2023-07-06 |
CN114555592A (zh) | 2022-05-27 |
KR20220079921A (ko) | 2022-06-14 |
AR120170A1 (es) | 2022-02-02 |
PE20221453A1 (es) | 2022-09-21 |
CO2022004341A2 (es) | 2022-04-29 |
US11548865B2 (en) | 2023-01-10 |
CU20220023A7 (es) | 2022-11-07 |
CL2022000893A1 (es) | 2023-01-20 |
ZA202202912B (en) | 2023-04-26 |
US20210107889A1 (en) | 2021-04-15 |
TW202128649A (zh) | 2021-08-01 |
AU2020361735B2 (en) | 2024-04-18 |
EP4041389A1 (en) | 2022-08-17 |
WO2021070090A1 (en) | 2021-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY38297A (es) | Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos | |
CL2022001392A1 (es) | Compuestos tricíclicos sustituidos | |
CO2019008531A2 (es) | Análogos de atazanavir (atv) para tratar infecciones por vih. | |
CL2021002883A1 (es) | Moduladores de thr-ß y métodos de uso de estos | |
BR112022012641A2 (pt) | Compostos tricíclicos substituídos | |
AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
AR050407A1 (es) | Compuestos quinolinon-carboxamida como agonistas del receptor 5-ht4. procesos de obtencion y composiciones farmaceuticas | |
UY31940A (es) | Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones | |
CL2022000893A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
CO2019011604A2 (es) | Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos | |
CO2022004391A2 (es) | Derivados de 5-oxa-2–azaespiro[3.4]octano como agonistas de m4 | |
CO2019010804A2 (es) | Derivados de indol n–sustituidos | |
CR20180323A (es) | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 | |
AR081725A1 (es) | Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer | |
CL2020001817A1 (es) | Moduladores del receptor c5a | |
CO2018001700A2 (es) | Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos | |
ECSP21011232A (es) | Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende | |
CL2020002188A1 (es) | Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmacéutico. | |
CO6361921A2 (es) | 3-aminociclopentancarboxamidas | |
AR107937A1 (es) | Compuestos de cinolin-4-amina y su uso en el tratamiento del cáncer | |
PE20201148A1 (es) | Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
AR127254A1 (es) | Ciertas octahidrofuro[3,4-b]pirazinas como moduladores del receptor de glp-1 | |
AR116428A1 (es) | Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo | |
PE20211454A1 (es) | Derivados de imidazopiridina y su uso como medicamento |